Progranulin Overexpression Predicts Overall Survival in Patients with Glioblastoma

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2011 Dec 14

PMID 22161130

Citations 29

Authors

Minqing Wang

Gang Li

Junyi Yin

Tao Lin

Jian Zhang

Affiliations

Soon will be listed here.

Abstract

Despite multimodal treatment, patients with astrocytoma still face a poor survival, and identification of valuable prognostic factors is crucial to yield effective individual therapy strategies. The aim of this study was to investigate progranulin (PGRN) expression in astrocytomas and explore its association with tumor grade and overall patient survival by scoring the PGRN immunoreactivity of both tumor cells and blood vessels. About 210 astrocytoma samples with different WHO grades and 14 normal brain tissues were studied by immunohistochemistry for PGRN. Semi-quantitative RT-PCR and Western blot were carried out to confirm its expression in 35 tumor specimens. Serum levels of PGRN in glioblastoma were examined by enzyme immunometric assay. PGRN expression was almost undetectable in the normal brain tissues by immunohistochemistry but increased in both astrocytoma cells and tumor blood vessels with pathological grading. Sera in glioblastoma were significantly higher than in healthy control. In grade II astrocytoma, strong vascular PGRN expression was closely related to tumor recurrence. In glioblastoma, high total PGRN expression, strong vascular PGRN expression, and strong tumor cellular PGRN expression all correlated with decreased patient survival in univariate analysis. However, only total PGRN expression as well as vascular PGRN expression status was independently associated with patient's survival in the multivariate analysis. These results suggest that PGRN, involved in astrocytoma progression, may serve as a prognostic biomarker for glioblastoma.

Citing Articles

The Role of Progranulin (PGRN) in the Pathogenesis of Glioblastoma Multiforme.

Poniatowski L, Woznica M, Wojdasiewicz P, Mela-Kalicka A, Romanowska-Prochnicka K, Purrahman D Cells. 2024; 13(2).

PMID: 38247816 PMC: 10814625. DOI: 10.3390/cells13020124.

Glioblastoma biomarkers in urinary extracellular vesicles reveal the potential for a 'liquid gold' biopsy.

Hallal S, Tuzesi A, Sida L, Xian E, Madani D, Muralidharan K Br J Cancer. 2024; 130(5):836-851.

PMID: 38212481 PMC: 10912426. DOI: 10.1038/s41416-023-02548-9.

Progranulinopathy: A diverse realm of disorders linked to progranulin imbalances.

Huang G, Jian J, Liu C Cytokine Growth Factor Rev. 2023; 76:142-159.

PMID: 37981505 PMC: 10978308. DOI: 10.1016/j.cytogfr.2023.11.001.

GRN is a prognostic biomarker and correlated with immune infiltration in glioma: A study based on TCGA data.

Xu S, Xiao H, Hu Z, Zhong X, Zeng Y, Wu Y Front Oncol. 2023; 13:1162983.

PMID: 37091137 PMC: 10117795. DOI: 10.3389/fonc.2023.1162983.

Progranulin Oncogenic Network in Solid Tumors.

Ventura E, Ducci G, Benot Dominguez R, Ruggiero V, Belfiore A, Sacco E Cancers (Basel). 2023; 15(6).

PMID: 36980592 PMC: 10046331. DOI: 10.3390/cancers15061706.

References

Kim W, Serrero G . PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells. Clin Cancer Res. 2006; 12(14 Pt 1):4192-9. DOI: 10.1158/1078-0432.CCR-05-2663. View

Dhermain F, Saliou G, Parker F, Page P, Hoang-Xuan K, Lacroix C . Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas. J Neurooncol. 2009; 97(1):81-8. DOI: 10.1007/s11060-009-9992-3. View

Tkaczuk K, Yue B, Zhan M, Tait N, Yarlagadda L, Dai H . Increased Circulating Level of the Survival Factor GP88 (Progranulin) in the Serum of Breast Cancer Patients When Compared to Healthy Subjects. Breast Cancer (Auckl). 2011; 5:155-62. PMC: 3140268. DOI: 10.4137/BCBCR.S7224. View

Liu Q, Li G, Li R, Shen J, He Q, Deng L . IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol. 2010; 100(2):165-76. DOI: 10.1007/s11060-010-0158-0. View

Liau L, Lallone R, Seitz R, Buznikov A, Gregg J, Kornblum H . Identification of a human glioma-associated growth factor gene, granulin, using differential immuno-absorption. Cancer Res. 2000; 60(5):1353-60. View

Kamrava M, Simpkins F, Alejandro E, Michener C, Meltzer E, Kohn E . Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer. Oncogene. 2005; 24(47):7084-93. DOI: 10.1038/sj.onc.1208857. View

Monami G, Emiliozzi V, Bitto A, Lovat F, Xu S, Goldoni S . Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth. Am J Pathol. 2009; 174(3):1037-47. PMC: 2665763. DOI: 10.2353/ajpath.2009.080735. View

Tangkeangsirisin W, Serrero G . PC cell-derived growth factor (PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cells. Carcinogenesis. 2004; 25(9):1587-92. DOI: 10.1093/carcin/bgh171. View

He Z, Bateman A . Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med (Berl). 2003; 81(10):600-12. DOI: 10.1007/s00109-003-0474-3. View

10.

Ho J, Ip Y, Cheung S, Lee Y, Chan K, Wong S . Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology. 2008; 47(5):1524-32. DOI: 10.1002/hep.22191. View

11.

Cheung S, Cheung P, Cheng C, Wong N, Fan S . Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology. 2010; 140(1):344-55. DOI: 10.1053/j.gastro.2010.07.049. View

12.

Cheung S, Wong S, Leung K, Chen X, So S, Ng I . Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Clin Cancer Res. 2004; 10(22):7629-36. DOI: 10.1158/1078-0432.CCR-04-0960. View

13.

Chen X, Li J, Liang Q, He D, Zhao J . Expression of PC cell-derived growth factor and vascular endothelial growth factor in esophageal squamous cell carcinoma and their clinicopathologic significance. Chin Med J (Engl). 2008; 121(10):881-6. View

14.

Arrieta O, Garcia E, Guevara P, Garcia-Navarrete R, Ondarza R, Rembao D . Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer. 2002; 94(12):3210-8. DOI: 10.1002/cncr.10594. View

15.

Elkabets M, Gifford A, Scheel C, Nilsson B, Reinhardt F, Bray M . Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest. 2011; 121(2):784-99. PMC: 3026724. DOI: 10.1172/JCI43757. View

16.

Davidson B, Alejandro E, Florenes V, Goderstad J, Risberg B, Kristensen G . Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer. 2004; 100(10):2139-47. DOI: 10.1002/cncr.20219. View

17.

Liu Y, Xi L, Liao G, Wang W, Tian X, Wang B . Inhibition of PC cell-derived growth factor (PCDGF)/granulin-epithelin precursor (GEP) decreased cell proliferation and invasion through downregulation of cyclin D and CDK4 and inactivation of MMP-2. BMC Cancer. 2007; 7:22. PMC: 1794415. DOI: 10.1186/1471-2407-7-22. View

18.

Pan C, Kinch M, Kiener P, Langermann S, Serrero G, Sun L . PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Clin Cancer Res. 2004; 10(4):1333-7. DOI: 10.1158/1078-0432.ccr-1123-03. View

19.

Serrero G, Ioffe O . Expression of PC-cell-derived growth factor in benign and malignant human breast epithelium. Hum Pathol. 2003; 34(11):1148-54. DOI: 10.1016/s0046-8177(03)00425-8. View

20.

He Z, Ismail A, Kriazhev L, Sadvakassova G, Bateman A . Progranulin (PC-cell-derived growth factor/acrogranin) regulates invasion and cell survival. Cancer Res. 2002; 62(19):5590-6. View